Could a nanodevice eliminate immunotherapy side effects in breast cancer?

October 31, 2018

The device is inserted straight into a tumour, making it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several intravenous treatments over a prolonged time.

Invented by Alessandro Grattoni, PhD, chairman of the Department of Nanomedicine at the Houston Methodist Research Institute, this tiny device can deliver the immunotherapy of choice little by little, gradually releasing the drug from its reservoir.